Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | PRKCH | P24723 | 1/20 | 0.35 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 6/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PAK4 | O96013 | 1/20 | 0.33 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5299 | 0.86 | SOS1 (0.38) | SOS1PRKCHPRKCEGRIA1DPP4 | |
| SCHEMBL717872 | 0.85 | PRKCH (0.38) | SOS1PRKCHPRKCEGRIA1PRMT5 | |
| SCHEMBL717871 | 0.85 | PRKCH (0.38) | SOS1PRKCHPRKCEGRIA1PRMT5 | |
| SCHEMBL714109 | 0.83 | SOS1 (0.37) | SOS1PRKCHPRKCEGRIA1PRMT5 | |
| SCHEMBL714110 | 0.83 | SOS1 (0.37) | SOS1PRKCHPRKCEGRIA1PRMT5 | |
| SCHEMBL717883 | 0.79 | SOS1 (0.36) | SOS1PRKCHPRKCEGRIA1PRMT5 | |
| SCHEMBL8072 | 0.79 | SOS1 (0.36) | SOS1PRKCHPRKCEGRIA1PRMT5 | |
| SCHEMBL714757 | 0.73 | L3MBTL1 (0.36) | — | |
| SCHEMBL715530 | 0.72 | PIK3CD (0.39) | SOS1PRKCHPRKCE | |
| SCHEMBL14480684 | 0.71 | SOS1 (0.37) | SOS1PRKCHPRKCEGRIA1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | SOS1 1414/4885PRKCH 396/4885PRKCE 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.